These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 33657636

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
    Bjornson C, Chan P, Li A, Paes B, Lanctôt KL, Mitchell I.
    Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1113-1118. PubMed ID: 29557081
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).
    Wang DY, Li A, Paes B, Mitchell I, Lanctôt KL, CARESS Investigators.
    Eur J Pediatr; 2017 Mar; 176(3):413-422. PubMed ID: 28105526
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab.
    Paes B, Saleem M, Kim D, Lanctôt KL, Mitchell I.
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1561-1568. PubMed ID: 31119575
    [Abstract] [Full Text] [Related]

  • 10. Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab.
    Wang DY, Saleem M, Paes BA, Mitchell I, Li A, Lanctôt KL, CARESS Investigators.
    Pediatr Infect Dis J; 2019 Aug; 38(8):775-780. PubMed ID: 30985509
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Palivizumab Adherence and Outcomes in Canadian Aboriginal Children.
    Hui C, Paes B, Papenburg J, Mitchell I, Li A, Lanctôt KL, CARESS Investigators.
    Pediatr Infect Dis J; 2016 Nov; 35(11):1187-1193. PubMed ID: 27331856
    [Abstract] [Full Text] [Related]

  • 13. Respiratory syncytial virus (RSV) infection in children with medical complexity.
    Lim A, Butt ML, Dix J, Elliott L, Paes B.
    Eur J Clin Microbiol Infect Dis; 2019 Jan; 38(1):171-176. PubMed ID: 30374685
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
    Packnett ER, Winer IH, Larkin H, Oladapo A, Gonzales T, Wojdyla M, Goldstein M, Smith VC.
    Hum Vaccin Immunother; 2022 Nov 30; 18(6):2140533. PubMed ID: 36412253
    [Abstract] [Full Text] [Related]

  • 16. Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015).
    Li A, Wang DY, Lanctôt KL, Mitchell I, Paes BA, CARESS Investigators.
    Pediatr Infect Dis J; 2017 May 30; 36(5):445-450. PubMed ID: 28403044
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
    Ordóñez JE, Huertas VM.
    BMC Infect Dis; 2024 Apr 19; 24(1):418. PubMed ID: 38641577
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.